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Abstract
Background: Sputum microscopy, the most important conventional test for tuberculosis, is
specific in settings with high burden of tuberculosis and low prevalence of non tuberculous
mycobacteria. However, the test lacks sensitivity. Although bacteriophage-based tests for
tuberculosis have shown promising results, their overall accuracy has not been systematically
evaluated.
Methods: We did a systematic review and meta-analysis of published studies to evaluate the
accuracy of phage-based tests for the direct detection of M. tuberculosis in clinical specimens. To
identify studies, we searched Medline, EMBASE, Web of science and BIOSIS, and contacted authors,
experts and test manufacturers. Thirteen studies, all based on phage amplification method, met our
inclusion criteria. Overall accuracy was evaluated using forest plots, summary receiver operating
(SROC) curves, and subgroup analyses.
Results: The data suggest that phage-based assays have high specificity (range 0.83 to 1.00), but
modest and variable sensitivity (range 0.21 to 0.88). The sensitivity ranged between 0.29 and 0.87
among smear-positive, and 0.13 to 0.78 among smear-negative specimens. The specificity ranged
between 0.60 and 0.88 among smear-positive and 0.89 to 0.99 among smear-negative specimens.
SROC analyses suggest that overall accuracy of phage-based assays is slightly higher than smear
microscopy in direct head-to-head comparisons.
Conclusion: Phage-based assays have high specificity but lower and variable sensitivity. Their
performance characteristics are similar to sputum microscopy. Phage assays cannot replace
conventional diagnostic tests such as microscopy and culture at this time. Further research is
required to identify methods that can enhance the sensitivity of phage-based assays without
compromising the high specificity.
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Background
Tuberculosis (TB) is a leading cause of morbidity and
mortality worldwide. According to the World Health
Organization, about one-third of the world's population
is infected with Mycobacterium tuberculosis, and about 8
million new cases of TB occur each year. Despite this large
burden and intensive control efforts, only about 46% of
the new infectious TB cases are detected each year [1].
Conventional TB diagnostics include sputum microscopy
and culture of M. tuberculosis. Although microscopy is sim-
ple, specific and rapid, it suffers from low sensitivity (30–
70%) [2]. Microscopy is particularly insensitive in HIV-
infected populations. The laboratory turn around time for
M. tuberculosis growth on solid culture media is around
eight weeks. Cultures on liquid media are more rapid.
Although the cost of liquid cultures has recently been
reduced, most hospitals in developing countries may not
find the test affordable. Low-income countries needs diag-
nostic tools that are sensitive, specific, cost effective, easy
to perform, and easy to implement within the current
infrastructure [3].
Among the various alternative diagnostic tests being eval-
uated, tests based on mycobacteriophages have shown
promise [4]. Phage-based tests are relatively easy to per-
form, but requires the type of laboratory infrastructure
that is needed for routine mycobacterial cultures. The
turnaround time of phage-based tests is 2 days compared
to about 2 hours (microscopy) or up to 2 months (cul-
ture). Two large-scale studies have shown that the test
detected 65–83% of the confirmed TB cases within 48
hours; the specificity of the tests in each of the studies was
>95% [5,6]. The assay could offer new tools for the rapid
diagnosis of TB in both the developed and developing
world [3-18]. However, it is important to systematically
review the literature and summarize the current evidence
on these new assays.
Two main phage-based approaches are used to detect M.
tuberculosis (Figure 1) [see Additional file]: (i) amplifica-
tion of phages after their infection of M. tuberculosis, fol-
lowed by detection of progeny phages using helper cells
(plaque formation); and (ii) detection of light produced
by luciferase reporter phages (LRP) by live M. tuberculosis
[3]. Phage-based tests are available as commercial kits
(e.g. FASTPlaque-TB® and PhageTek MB®, a name variant
of the FASTPlaque-TB, Biotec Laboratories Ltd, UK) [14]
and as in-house (laboratory-developed) assays [15]. In-
house tests use either amplification technology (e.g.
phage amplified biologically [PhaB]) or LRPs. Some of the
phage-based tests are designed to rapidly detect rifampin
resistance (e.g. FASTPlaque-MDRi) in culture isolates.
Existing studies show that the accuracy of phage based
tests might vary [18]. Because traditional reviews are often
subjective, less comprehensive, and rely on qualitative
methods [19], we conducted a systematic review to evalu-
ate the overall accuracy of phage-based tests for the direct
detection of M. tuberculosis in clinical specimens. We
addressed the following questions in our review:
1. What is the overall accuracy of phage-based tests com-
pared to the gold standard, culture?
2. What is the overall accuracy of phage-based tests com-
pared to smear microscopy?
3. How does the accuracy of phage-based tests vary by spu-
tum smear status?
Methods
Search strategy and selection criteria
We searched the following electronic databases: PubMed
(1985–2004), Web of Science (1985–2004), EMBASE
(1988–2004), and BIOSIS (1993–2004). All searches
were up to date as of November 2004. The search terms
included "tuberculosis," "Mycobacterium tuberculosis,"
"mycobacteria," "bacteriophages," "mycobacteriophage,"
"phage," "FASTPlaque," "phage amplification," "phage-
based," "bacteriophage-based," "sensitivity and specifi-
city", "accuracy" and "predictive value". We also searched
the reference lists from the primary studies and review
articles, sought help from experts in the field, and
obtained lists of studies from companies that manufac-
ture commercial rests. Although we did not impose lan-
guage restriction while searching, we included only
English language articles for our review.
We followed a written protocol and explicit study selec-
tion criteria. Studies were included in the review if they
met the following criteria: comparison of phage test
against a reference standard, data necessary for the com-
putation of both sensitivity and specificity, and culture
(either liquid or solid media) as the reference standard.
Two reviewers (SK and MP) independently screened the
titles and abstracts to identify eligible studies. Disagree-
ments between the reviewers were resolved by consensus.
A list of excluded studies, along with the reasons for exclu-
sion is available from the authors on request.
Data abstraction and quality assessment
The final set of included articles was assessed by one
reviewer (SK), who extracted data from all the studies
using a piloted data extraction form. A second reviewer
(MP) independently extracted data from a subset of the
included studies to evaluate reproducibility of data extrac-
tion. The inter-rater agreement between the two reviewers
was 100%. Data retrieved from the reports included meth-
odological quality, participant characteristics, laboratory
methods, and outcome data (sensitivity and specificity).BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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Bacteriophage-based assays for diagnosis of tuberculosis Figure 1
Bacteriophage-based assays for diagnosis of tuberculosis.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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We assessed the quality of the studies by using criteria
selected from the QUADAS checklist [20] for assessment
of quality of diagnostic studies: study design (cross-sec-
tional versus case-control), blinding (single/double blind
versus unblinded interpretation of index test and refer-
ence standard results), and potential for verification bias
(complete versus partial/differential verification of index
test results by reference standards).
To compute sensitivity and specificity of phage-based
assays, we chose sputum culture on solid and/or liquid
media (e.g. BACTEC 460) as the reference standard in our
review. To compare the accuracy of phage based assays
with sputum microscopy, we evaluated studies that
reported head-to-head comparisons of sputum micros-
copy with phage based assays (against a common refer-
ence standard) and computed the diagnostic yield of
phage based assays over and above sputum microscopy.
To evaluate the effect of sputum-smear status on accuracy,
we conducted subgroup analyses for smear-positive and
smear-negative specimens.
Statistical analysis
We used standard methods recommended for meta-anal-
yses of diagnostic test evaluations [21]. Data were ana-
lyzed with Meta-Disc (version 1.1.1) software [22]. Our
analyses focused on the following measures of diagnostic
accuracy: sensitivity (true positive rate [TPR]), and specif-
icity (1-false positive rate [FPR]).
Each study in the meta-analysis contributed a pair of
numbers: TPR and FPR. Since these measures are corre-
lated and vary with the thresholds (cut points), it is cus-
tomary to analyze TPR and FPR proportions as pairs, and
to also explore the effect of threshold on study results
[23]. We summarized the joint distribution of sensitivity
and specificity using the Summary Receiver Operating
Characteristic (SROC) curve. Unlike a traditional Receiver
Operating Characteristic plot that explores the effect of
varying thresholds on sensitivity and specificity in a single
study, each data point in the SROC space represents a sep-
arate study. The SROC curve is obtained by fitting a regres-
sion curve to pairs of TPR and FPR. The SROC curve and
the area under it present an overall summary of test per-
formance, and display the trade off between sensitivity
and specificity. A symmetric, shoulder-like SROC curve
suggests that variability in thresholds employed could, in
part, explain variability in study results [19]. The area
under the SROC curve is a global measure of overall test
accuracy. An area under the curve of 100% indicates per-
fect discriminatory ability.
Heterogeneity in meta-analysis refers to a high degree of
variability in study results [24]. Such heterogeneity could
be due to variability in thresholds, disease spectrum, test
methods, and study quality across studies [24]. In the
presence of significant heterogeneity, pooled, summary
estimates from meta-analyses are not meaningful. We
investigated heterogeneity using subgroup analyses. Meta-
regression was not attempted because of the small
number of studies identified.
Results
Study selection
Figure 2 describes the study selection process. Thirteen
studies from 12 articles [5-13,15-17], of the 532 articles
identified, met our eligible criteria, and were included in
our final analyses.
Description of included studies
Studies included in the final analyses are summarized in
Table 1. The total number of samples analysed in all the
studies were 5820 (mean 448); 1330 (23%) of the sam-
ples were culture positive. Most studies enrolled subjects
with suspected pulmonary tuberculosis, as suggested by
history, physical examination or chest radiograph. Three
studies [8,16,17] included non-respiratory specimens
(urine, CSF, pleural fluid and lymph node aspirate], in
addition to sputa. Except one [9], no study provided data
on age range, sex ratio and prevalence of HIV. In half the
studies, patients had received some treatment before they
were evaluated. The study design was cross-sectional in 11
of 13 (85%) [5-13,15], and case-control in 2 studies
(15%) [11,17]. Only 2 [13,15] of 13(15%) studies
reported blinded comparison of the phage based assays
with the reference standard. No study had potential for
incorporation bias.
Study flow Figure 2
Study flow.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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Assay characteristics
All studies (except one that classified any visible plaques
as positive [15] used the same cut point for the phage
amplification assay: 20 or more plaques were reported as
a positive test. No study used luciferase reporter phages to
detect M. tuberculosis in clinical specimens. Sputum sam-
ples were processed by a standard N-acetyl-L-cysteine-
sodium hydroxide (NALC-NaOH) method in all studies
evaluating commercial phage-based assays. Only three
studies [6,7,13] reported the proportion of the phage tests
or the reference tests that were contaminated. Non-tuber-
culous mycobacteria (NTM) were grown in 4 studies
[6,9,10,17], but most studies provided no data on what
proportion of the NTM isolates were positive by the phage
test. Six studies [6,9,11-13,15] had used LJ cultures as the
reference standard; three studies [5,7,10] used BACTEC
460; three studies [8,17] used LJ and BACTEC methods
and one study [13] used LJ and AMTD tests. The index test
was FASTPlaque in 10 studies [5-8,10-13,16,17],
PhageTek in 1 study [9] and in-house amplification assays
in 2 studies [13,15]. None of the studies used LRP assays.
Most studies reported sensitivity and specificity data with
specimens as the unit of analysis (not individuals).
Overall accuracy of phage assays
We identified 13 studies that assessed the sensitivity of
phage-based assays (Table 2, Figure 3). Sensitivity is the
proportion of patients with culture-proven tuberculosis
who are positive by phage-based assays. Overall, as seen
in Figure 3, the sensitivity of the phage based assays varied
widely, from 0.21 to 0.94 (test of heterogeneity: p <
0.001). Because of the significant heterogeneity, sensitiv-
ity estimates were not pooled. Three studies [9,11,13]
reported very low sensitivity.
Thirteen studies assessed the specificity of phage-based
assays (Table 2, Figure 3). Specificity is the proportion of
individuals without tuberculosis (culture-negative) who
are negative by the phage- based assay. The specificity esti-
mates were high and fairly consistent across the studies
(range: 0.83 to 1.00). Except two studies [9,17] that
reported false- positive rates of 14% and 17% respectively;
all other studies reported >90% specificity. The in-house
assays were as specific as commercials assays.
Figure 4 presents the sensitivity and specificity estimates
in a SROC space. The curve shows that most studies had
Table 1: Study characteristics and methodological quality of included studies
Study Characteristics Frequency
Study Design
Cross-sectional 11
Case-control 2
Verification of phage tests with reference standard
Complete 13
Partial 0
Blind assessment of phage tests and reference standard results
Yes 3
Unclear 10
Test before treatment
Yes 6
No 5
Unclear 2
Year of Publication
Before 2002 4
After 2002 9
Study size
< 20% positive specimens 2
> 20% positive specimens 11
Reference standard
BACTEC 460 3
LJ medium 6
Bactec and LJ* 3
LJ/AMTD** 1
Type of assay
Commercial 11
In-house 2
*LJ: Lowenstein Jensen medium
**AMTD: Amplified Mycobacterium tuberculosis Direct TestBMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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high specificity with lower and highly variable estimates
of sensitivity. Although the area under the curve was 0.95,
significant heterogeneity in the sensitivity estimates pre-
cluded the determination of clinically meaningful sum-
mary estimates of accuracy.
Effect of sputum smear status on accuracy of phage tests
Because phage-based assays have threshold of detection of
about 100 viable bacilli, they are expected to perform bet-
ter in smear-positive samples compared to smear- nega-
tive ones. We performed subgroup analysis to evaluate
this hypothesis. Five studies [5,6,8-10] provided estimates
of accuracy, stratified by smear status (Table 3, Figure 5).
Smear-positive specimens tended to yield higher esti-
mates of sensitivity than smear-negative specimens. The
sensitivity ranged between 0.29 and 0.87 in smear posi-
tive and 0.13 to 0.78 in smear negative specimens. The
specificity ranged between 0.60 and 0.88 among smear
positive specimens and 0.89 to 0.99 in smear negative
specimens.
Head-to-head comparisons against sputum microscopy
Ten studies – 8 commercial [5-10,12,13] and 2 in-house
[13,15] – provided data on head-to-head comparisons of
sputum microscopy with phage based assays, against a
common reference standard viz. culture [Table 4; Figure
6]. Eight studies reported staining sputum smears with
Ziehl – Neelsen technique [6,7,9-12,16,17], whereas four
studies used fluorescent microscopy [5,8,13,15]. Except
three studies [5-7], other studies did not report clinically
meaningful higher sensitivity for the phage assays.
Interestingly, the sensitivity of phage based assays was
lower than that of microscopy in four studies [8,9,13,15].
The SROC plots [Figure 6] suggest that phage assays have
a slightly higher accuracy than microscopy (area under the
SROC curve was 0.95 for phage assays, whereas it was 0.86
for microscopy).
Discussion
Overall accuracy of phage-based tests
Our results indicate that phage-based assays are highly
specific but not sensitive enough to be equivalent to
culture. Phage-based assays detected M. tuberculosis in
one-half to two thirds of sputum samples with specificity
Table 2: Description of studies in the meta-analysis and measures of test accuracy
Source Country Study 
Design
Blinding Complete 
verification
Specimen Treatment 
status
Test Patients 
With TB 
(No./
Overall)
Reference 
Standard
Sensitivity 
(95%CI)
Specificity 
(95%CI)
Commercial assays
Albay 
(2003)
Turkey CS Unclear Yes Sputum Untreated FASTPlaque 64/192 BACTEC 0.88 (0.77,
.94)
0.97 (0.92,
0.99)
Albert 
(2002)
South 
Africa
CS Unclear Yes Sputum Untreated FASTPlaque 207/1618 BACTEC 0.72
(0.66,0.78
0.99
(0.98,0.99)
Alcaide 
(2003)
Spain CS Unclear Yes Sputum+ 
other
Some 
treated
FASTPlaque 144/2048 B+LJ 0.58
(0.50,0.66)
0.99
(0.99,0.99)
Bellen 
(2003)
Philippines CS Unclear Yes Sputum Some 
treated
Phage Tek 103/206 LJ 0.31
(0.22,0.41)
0.86
(0.78,0.92)
Butt (2004) Pakistan CS Unclear Yes Sputum Untreated FASTPlaque 60/160 BACTEC 0.77
(0.64,0.87)
0.96
(0.90,0.99)
Cavusoglu 
(2002)
Turkey CC Unclear Yes Sputum Some 
treated
FASTPlaque 33/63 LJ 0.30
(0.15,0.49)
0.97
(0.83,1.00)
Marei 
(2003)
Egypt CS Unclear Yes Sputum Untreated FASTPlaque 60/160 BACTEC 0.77
(0.64,0.87)
0.96
(0.90,0.99)
Mbulo 
(2004)
Zambia CS Yes Yes Sputum Untreated FASTPlaque 29/115 LJ 0.21
(0.08,0.40)
0.91
(0.82,0.96)
Muzaffar 
(2002)
Pakistan CS Unclear Yes Sputum NR FASTPlaque 103/1209 LJ 0.82
(0.76,0.86)
0.98
(0.95,0.99)
Shenai 
(2002)
India CS Unclear Yes Sputum+ 
other
Some 
treated
FASTPlaque 62/90 BACTEC+LJ 0.76
(0.60,0.89)
1.00
(0.74,1.00)
Shenai 
(2004)
India CC Unclear Yes Sputum+ 
other
Some 
treated
FASTPlaque 103/129 BACTEC+LJ 0.94
(0.79,0.99
0.83
(0.52,0.98)
In- house assays
McNerney 
(2004)
Zambia CS Yes Yes Sputum NR In-house 220/496 LJ 0.44
(0.37,0.51)
0.92
(0.89,0.95)
Mbulo 
(2004)
Zambia CS Yes Yes Sputum Untreated In – house 245/514 LJ+AMTD 0.45
(0.32,0.60)
0.95
(0.85,0.99)
Abbreviations: CS, cross-sectional studies; CC, case-control studies; NR, Not recorded.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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that ranged between 0.83 and 1.00. On the other hand,
sensitivities varied between 0.21 and 0.94. Ten of the 13
studies used FASTPlaque-TB kit; the two studies that used
in-house assays were less accurate than the commercial
assays.
Forest plots of estimates of sensitivity and specificity for commercial and in-house assays Figure 3
Forest plots of estimates of sensitivity and specificity for commercial and in-house assays. circle: commercial assays; rectangles: 
in-house assays. Error bars represent 95% CIs.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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Because of heterogeneity in estimates of accuracy across
studies, we did not calculate pooled estimates of sensitiv-
ity and specificity. What factors might explain the
observed heterogeneity? The differences in the extent of
treatment given to patients prior to collecting specimens,
the potential differences in timeliness of specimen trans-
port and processing may have had impacts on the number
of viable bacilli in the specimens. Since the phage-based
Summary receiver operating characteristic (SROC) curves for commercial and in-house assays Figure 4
Summary receiver operating characteristic (SROC) curves for commercial and in-house assays. Each circle (commercial assay) 
and rectangle (in-house assay) represents an individual study.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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Table 3: Sensitivity and specificity of phage assays in studies that reported results stratified by smear microscopy status
Sputum smear microscopy status
Smear positive Smear negative
Study Country Number of
Specimens (culture
positive)
Sensitivity Specificity Sensitivity Specificity
Albert (2002) South Africa 1618 (207) 0.87 (0.79,0.92) 0.83 (0.69,0.93) 0.49 (0.37,0.60) 0.99 (0.99,1.00)
Alcaide (2003) Spain 2048 (144) 0.75 (0.66,0.83) 0.76 (0.55,0.91) 0.13 (0.04,0.27) 0.99 (0.99,1.00)
Bellen (2003) Philippines 206 (103) 0.29 (0.20, 0.40) 0.83 (0.67,0.93) 0.45 (0.17,0.77) 0.89 (0.78,0.95)
Butt (2004) Pakistan 160 (60) 0.76 (0.60, 0.88) 0.60 (0.15,0.95) 0.78 (0.52,0.93) 0.98 (0.93,1.00)
Muzaffar (2002) Pakistan 514 (245) 0.87 (0.82,0.92) 0.88 (0.63,0.98) 0.67 (0.55,0.78) 0.98 (0,96,1.00)
Forest plots of estimates of sensitivity and specificity for smear positive and smear negative specimens Figure 5
Forest plots of estimates of sensitivity and specificity for smear positive and smear negative specimens.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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assay detects only viable mycobacteria, and has a
threshold of detection of about 100 viable bacilli, any
factor that impacts viability of TB bacilli can affect sensi-
tivity of the assay. Of the 5 studies of commercial assays in
patients who were not treated prior to specimen collec-
tion, 4 studies reported sensitivities of 0.72 or greater.
Table 4: Head-to-head comparison between smear microscopy and phage assays
Smear microscopy Phage test Difference (Phage – Microscopy)
Study Year Sample size Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Commercial assays
Albay 2003 192 0.58 (0.44,0.70) 1.00 (0.97,1.00) 0.88 (0.77,0.94) 097 (0.92,0.99) 0.30 - 0.03
Albert 2002 1618 0.62 (0.55,0.69) 0.97 (0.96, 0.98) 0.72 (0.66,0.78) 0.99 (0.98,0.99) 0.10 0.02
Alcaide 2003 2048 0.73 (0.65,0.80) 0.99 (0.98,0.99) 0.58 (0.50,0.66) 0.99 (0.99,0.99) -0.15 0
Bellen 2003 204 0.89 (0.82,0.95) 0.60 (0.50,0.70) 0.31 (0.22,0.41) 0.86 (0.78, 0.92) - 0.58 0.26
Butt 2004 160 0.70 (0.57.0.81) 0.95 (0.89,0.998) 0.77 (0.64, 0.87) 0.96 (0.90,0.99) 0.07 0.01
Marei 2003 38 0.64 (0.31,0.89) 0.93 (0.76, 0.99) 0.55 (0.23, 0.83) 1.00 (0.87, 1.00) -0.09 .07
Mbulo 2004 496 0.45 (0.32, 0.60) 0.98 (0.91, 1.00) 0.45 (0.32, 0.60) 0.91 (0.82, 0.96) 0 -.07
Muzaffar 2002 514 0.71 (0.65,0.77) 0,94 (0.90,0.96) 0.82 (0.76,0.86) 0.98 (0.95,0.99) 0.11 0.05
In- house assays
Mbulo 2004 115 0.48 (0.29, 0.60) 0.90 (0.81, 0.95) 0.21,(0.08,0.40) 0.91 (0.82,0.96) -0.27 0.14
McNerney 2004 496 0.60 (0.53,0.66) 0.87(0.83,0.91) 0.44 (0.37, 0.51) 0.92 (0.89,0.95) - 0.16 0.05
Summary receiver operating characteristic (SROC) curves for sputum microscopy and phage-based assays Figure 6
Summary receiver operating characteristic (SROC) curves for sputum microscopy and phage-based assays. Each solid circle 
represents a study in the meta-analysis.BMC Infectious Diseases 2005, 5:59 http://www.biomedcentral.com/1471-2334/5/59
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Conversely, only 2 of the 5 studies whose patient popula-
tion included those on anti-TB therapy had sensitivities
greater than 0.72. It is likely that anti-TB therapy in these
studies decreased the number of viable bacilli in speci-
mens. Further assessments of this issue should be made.
Another important issue that may have been responsible
for heterogeneity in sensitivity estimates was specimen
transport and the potential impact of environmental con-
ditions on specimen viability. Rapid processing of speci-
mens and timely initiation of the phage assay is
important: the sensitivity of the phage assay was 72%
when the specimens were processed immediately and
tests were performed daily [5] compared to the sensitivity
of 29% when the processing of the specimens was delayed
and the assays were run twice a week [9]. The specificity of
phage-assays for detecting acid fast bacilli is likely to
decrease in settings in which infection with mycobacteria
other than M. tuberculosis are common. Sodium hydrox-
ide, used to decontaminate the specimens, may damage
the acid fast bacilli and can reduce the sensitivity of phage-
based assays for detecting tuberculosis. Use of gentler
decontamination techniques can reduce the specificity of
the test: this approach protects the acid fast bacilli but fails
to prevent contamination from other microorganisms.
Contamination of LJ slants with micro-organisms is a
common problem in certain settings (40.4% in Zambia
[13] and 18.2% in Pakistan [6]). The exclusion of contam-
inated results may result in biased estimates of sensitivity
and specificity. This approach (partial verification) can
lead to bias if systematically more abnormal than normal
test results are subjected to the reference standard.
Although no study reported use of smear instead of
contaminated cultures, such a strategy could weaken the
reference standard and result in differential verification
bias.
The impact of HIV infection on test accuracy could not be
determined in this review because none of the studies
reported the proportion of HIV infections among the
tested population. Because HIV infection may impact the
extent of viable mycobacteria present in sputum speci-
mens, studies of populations with defined HIV status
should be performed. Also, the varying sensitivity of the
reference standard might have had an impact on the accu-
racy of the phage-based assays and could have contributed
to the heterogeneity. Because grouping the studies in four
sub-groups (LJ media, BACTEC media, LJ and BACTEC
and AMTD and LJ) would have resulted in small numbers
of studies in each of the category, we did not attempt sta-
tistical comparisons.
Accuracy of phage-based tests compared to smear 
microscopy
Although some phage-based studies proved to be more
sensitive than smear microscopy [5-7,10], others were not
[8,9,12,13,15]. Differences in performance of phage-
based tests compared to smear microscopy were also
determined for smear-positive and smear-negative, cul-
ture-positive specimens. Overall, sensitivity in smear-pos-
itive specimens appeared to be higher than in smear-
negative specimens, but among smear -negative speci-
mens, phage- based assays had high specificity.
To evaluate the accuracy of smear microscopy for detect-
ing M. tuberculosis, except one study [5] in which patients
provided two sputum specimens each, all studies used
only a single sputum sample. This approach differs from
the current World Health Organization (WHO) and
International Union against Tuberculosis and Lung Dis-
ease (IUATLD) recommendations, which state that at least
three sputum samples must be examined for each patient
[25]. Use of a single sample might make the smear micro-
scopy look less sensitive than what it actually it is because
the sensitivity may go up with greater number of smear
tests. It would be interesting to evaluate the additional
yield from repeated sputum examinations by microscopy
and culture and do a head-do-head comparison of 3 spu-
tum smears with phage-based assays. To our knowledge,
this has not been done in any of the available studies.
Non- tuberculous mycobacteria are also known to con-
tribute to false positive phage test results. The phage can
be amplified by almost any mycobacteria present in the
sputum and it is important to verify that the sputum
contains Mycobacterium tuberculosis complex. The effect of
non-tuberculosis mycobacteria (NTM) might be minimal
in places where true M. tuberculosis is very common (high
incidence settings). In settings with low incidence, NTM
might have a greater impact. A requirement for a confirm-
atory test would make the overall testing strategy more
expensive, delay the diagnosis, and result in an additional
patient visit to the laboratory. Clearly, these factors could
adversely impact the practical applicability of the test in
resource -limited settings with high burden of
tuberculosis.
Spectrum and selection bias are known to affect sensitivity
and specificity of a diagnostic test. Spectrum bias may
occur when the test is assessed in a study population with
a different clinical spectrum than will be found among
those in whom test is to be applied in clinical practice.
Specimens in several reviewed studies were collected from
patients reporting to tertiary care centres [10,11,16,17].
Such patients are more likely to have advanced disease
with a large bacillary load. Selection bias could also have
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phage-based assays – patients referred to chest clinics and
those with abnormal chest radiographs are more likely to
have a higher bacillary load. The referral bias can make the
phage-based assays appear more sensitive than they actu-
ally are.
Overall, our review suggests that when a patient's phage
test is negative, there is roughly one in three probability
that patient has tuberculosis. A negative test, therefore,
does not exclude tuberculosis in patients suspected to
have tuberculosis.
Strengths and weaknesses of the review
Our review has several strengths. We followed a written
protocol, performed a very comprehensive search of sev-
eral databases and sources to identify studies. We assessed
the quality of included studies by using established crite-
ria [20]. We also analyzed commercial and in-house
assays separately, to take into account the potential differ-
ences between the assay techniques. Lastly, we used sum-
mary ROC curves to take into account the impact of
varying thresholds and also the interdependence of sensi-
tivity and specificity.
Our review has some limitations. Most studies provided
no data on prevalence of TB and/or HIV in their study
population. Several studies did not specify whether the
specimens were collected before or after anti-TB therapy
was started. Most studies did not specify the volume and
quality of sputum specimens, the proportion of contami-
nated phage tests and indeterminate results. Most studies
did not specify if non-tuberculous mycobacteria were iso-
lated in the study. We could not analyse such factors as
laboratory infrastructure and expertise with phage assays
on the accuracy of phage assays. Although we explored the
issue of heterogeneity using subgroup analyses, tech-
niques such as meta-regression may be useful in the eval-
uation of heterogeneity. However, we were unable to
perform metaregression because we had only 13 studies in
our systematic review; with only 13 data points, it is diffi-
cult to fit and interpret a regression model. Also, because
of the small number of data points, we were unable to per-
form statistical comparisons between subgroups. Finally,
bias may have been introduced by the exclusion of non-
English language studies.
Clinical applicability and implications
Since many countries with a high TB burden do not use
culture, an inexpensive alternative diagnostic test is neces-
sary. One-third to two-thirds of all cases of pulmonary
tuberculosis are not being detected by the commonly used
smear microscopy [25]. Can phage-based tests be used to
diagnose pulmonary tuberculosis in high burden and lim-
ited resource settings? Although our review shows that
phage-based tests have high specificity, their sensitivity is
lower and highly variable. Also, they do not have substan-
tially higher accuracy than sputum microscopy. In addi-
tion, phage-based assays are much more complicated and
labor-intensive than microscopy and thus cannot be per-
formed in primary-care settings; they require a laboratory
infrastructure similar to that required for performing
cultures.
Although it can be argued that the rapid and specific diag-
nosis of 50% or more of TB patients can be made within
2 days, leading to reduced potential for ongoing transmis-
sion and more effective management of individual
patients [26], our review suggests that phage-based assays
need to have higher sensitivity before such potential
advantages can be realized. Mbulo et al [13] point out that
the main disadvantage of phage-based test compared to
sputum smear microscopy is that specimens need to be
transported to a specialist reference laboratory. The fact
that phage-based assays are more expensive than smear
microscopy, need a trained microbiologist makes them
less suitable in resource-poor settings. Also, it remains to
be seen how the test performs outside reference laborato-
ries. Molecular strain typing tests such as polymerase
chain reaction (PCR) are competitors for phage-based
assays. Of the two studies [7,12] that reported head to
head comparisons of molecular tests with phage – based
assays against a common reference test (i.e. culture), one
study [7] found no difference in test accuracy between the
phage-based assay and the polymerase chain reaction; the
other study [12] found that phage-based assay was less
sensitive (64% vs. 82%) but more specific (93% vs. 85%)
compared to the polymerase chain reaction.
Conclusion
Our review suggests that phage-based assays have high
specificity, but modest and variable sensitivity. Their accu-
racy is slightly higher than smear microscopy in head to
head comparisons. However, because of the overall low
sensitivity, the similarity of phage-based assays to sputum
microscopy with respect to accuracy, and the need for a
fairly advanced laboratory infrastructure, phage-based
assays cannot replace conventional diagnostic tests at this
point. Further research is required to identify methods
that can enhance the sensitivity of phage-based assays,
without compromising the high specificity.
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